Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
May 20, 2019

AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility

AbbVie has discontinued an ongoing phase 3 trial evaluating its antibody drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M) for the treatment of newly diagnosed glioblastoma (GBM), an aggressive type of brain cancer, owing to futility.

Image: Futility forces AbbVie to drop INTELLANCE-1 study of Depatux-M. Photo: courtesy of AbbVie Inc.